<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ehrlich, Joachim R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Pharmacotherapies in Atrial Fibrillation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-26</style></pages><abstract><style  face="normal" font="default" size="100%">The journey from sinus rhythm toward atrial fibrillation (AF) involves several types of atrial remodeling, including (among others) electrical, contractile, and structural remodeling. This article discusses the implications of atrial remodeling on the treatment of AF, future options for antiarrhythmic therapy, and hospitalization rate among other things.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>